Lung Cancer Master Protocol (Lung-MAP)


At a Glance
  • Status: Active Consortium
  • Year Launched: 2014
  • Initiating Organization: FNIH
  • Initiator Type: Government
  • Rare disease
  • Disease focus:
    Squamous Lung Cancer
  • Location: North America

Abstract

Lung-MAP (SWOG S1400) is a multi-drug, multi-sub-study, biomarker-driven squamous cell lung cancer clinical trial that uses state-of-the-art genomic profiling to match patients to sub-studies testing investigational treatments that may target the genomic alterations, or mutations, found to be driving the growth of their cancer. Instead of having to undergo multiple diagnostic tests to determine eligibility for many different studies, enrollees are tested just once according to a “master protocol” and assigned to one of multiple trial sub-studies, each testing a different drug from a different developer. That means shared information and infrastructure, better access for patients to promising drugs, better access for researchers to relevant enrollees based on their genomic profiles, and less time and money needed before investigational drugs can be tested.

Mission

The primary objective of each Lung-MAP trial sub-study is to learn whether a targeted cancer therapy that is matched to the genomic makeup of a patient’s lung cancer tumor is more effective than the current standard therapy in halting or reversing the progress of the disease and in extending the patient’s life. Researchers on each trial sub-study will also compare the tumor response rates and the frequency and severity of side effects patients experience on the targeted-therapy arm versus the standard-of-care arm.

Structure & Governance

Lung-MAP is a project of the National Clinical Trials Network, which is operated by the National Cancer Institute. 

Financing

Lung-MAP is funded as a project under the National Clinical Trials Network.

Patient Engagement

Lung-MAP is a large clinical trial, or research study, testing several new treatments for patients who have advanced stage squamous cell lung cancer. In advanced stage patients, the cancer has usually spread to other organs in their body. The Lung-MAP trial is for advanced stage patients whose cancer has continued to grow, even after being treated with standard therapy.

Impact/Accomplishment

For links to news and media relating to Lung-MAP, click here

Points of Contact

rhohman@focr.org

Sponsors & Partners

National Cancer Institute

National Clinical Trials Network

SWOG Cancer Research

Friends of Cancer Research

The Foundation for the National Institutes of Health

Amgen

Bristol-Myers Squibb

Genentech

Pfizer

AstraZeneca

MedImmune

Foundation Medicine

Addario Lung Cancer Foundation

Lung Cancer Alliance

LUNGevity Foundation

Free to Breathe

Lung Cancer Foundation of America

American Lung Association

American Cancer Society

Uniting Against Lung Cancer


Last Updated: 06/21/2017

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.